Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

Dear Editor,

We read with interest the recent article by Singh and Cleveland on the hypersensitivity risk of allopurinol (ALP) and febuxostat (FBX) compared with colchicine. A common challenge when using ALP, linked to hypersensitivity reactions, is the potential development of cutaneous adverse reactions (CARs). Most are often mild, non-specific rashes; however, severe CARs, including Stevens-Johnson syndrome (SJS), may occur, but with a low incidence (0.69 cases per 1000 person-years) in non-Asian populations. In the EuroSCARs study, ALP was the reason for 5% of all severe CARs. So, FBX is often chosen as urate-lowering agent on the background of an ALP-related CAR. However, these patients were not eligible for the pivotal trials of FBX and were excluded from the recent analysis by Singh and Cleveland. Therefore, the accurate rate of FBX-related CARs in patients who previously suffered from ALP, and the mechanisms behind, remain undetermined to date.

We have retrospectively reviewed patients with gout (diagnosed by crystals or American College of Rheumatology/European League Against Rheumatism criteria) treated with FBX after a previous CAR to ALP, from seven rheumatology units with members of the Crystal Arthritis Group of the Spanish Society of Rheumatology.

The study period spanned from 2011 (FBX commercialisation in Spain) to June 2018. Patients’ records were reviewed for demographics, clinical features (type of skin events, ALP and FBX starting doses and doses at the time of rash), and serum urate levels and glomerular filtration rates at the time of prescription. Our primary study variable was the rate (%) of patients developing skin reactions with FBX. Descriptive analysis with an estimation of the 95%CI is given.

The study centres provided 67 patients with gout and a previous ALP-related CAR who were later treated with FBX (Table 1). The median age was 71 years (p25-75 59.8–79.5), with 49 being male (73.1%). Most ALP cases were mild, but three developed SJS (Table 1). Starting dosing was variable, and the percentage of chronic kidney disease was 58.0%.

Ten of these 67 patients (14.9%, 95%CI 8.3% to 25.3%) also developed rash with FBX, with the same proportion between male and female. Median (p25-75) time from ALP-rash to FBX initiation was 5.0 months (1.0–71.8). Numbers of serum urate levels and estimated glomerular filtration rates were similar in this subgroup. Types of rash were variable; to note, one patient with prior ALP-related SJS also developed with FBX.

Benzbromarone was successfully initiated in 19 patients (seven with CAR with both ALP and FBX), only one also developing a non-specific rash.

Our multicentre data identified around 15% of patients with prior ALP-related CARs also developed them with FBX. This rate is higher than previously reported. In an initial series of 13 patients with ALP-related CAR, only one developed it with FBX, while 9% of reactions with ALP and FBX in a study with 113 patients was published in 2016. Despite having the same target (the xanthine oxidase), FBX and ALP have no similarities on biochemical structure, so the identified cross-reaction is intriguing. The likelihood of developing ALP-related CARs mainly depends on starting dose and renal function. In Europe, FBX is only licensed as 80 and 120 mg tablets, while 40 and 80 mg are available in the USA. Whether using FBX at lower dosage might reduce the incidence of cross-reactions with ALP merits investigation, but to note, in our series, one patient also developed CAR with FBX dispensed at 10 mg.

Further prospective and intervention studies are needed to confirm these results, although caution is recommended when using FBX in this subgroup of patients.

Neus Quilis, Paloma Vela, Boris A Blanco Cacerez, Cesar DiazTorne, Enrique Calvo Aranda, Francisca Sivera, Alejandro Prada Ojeda, Fernando Perez Ruiz, Eliseo Pascual, Mariano Andres

1Rheumatology Unit, Hospital Universitario del Vinalopó, Elche, Alicante, Spain
2Rheumatology Department, Hospital General Universitario de Alicante, Alicante, Spain
3Rheumatology, Hospital Universitario Cruces, Barakaldo, País Vasco, Spain
4Rheumatology, Hospital de la Santa Creus i Sant Pau, Barcelona, Spain
5Rheumatology, Hospital Universitario HM Sanchinarro, Madrid, Spain
6Medicine, Miguel Hernandez University of Elche Faculty of Medicine, Sant Joan D’Alacant, Spain
7Rheumatology, Hospital General Universitario Elda, Spain
8Rheumatology, Hospital Universitario de Torreviej, Torrejón de Ardoz, Madrid, Spain
9Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain
10Rheumatology, Hospital de Alicante, Alicante, Spain

Correspondence to Dr Neus Quilis, Rheumatology Unit, Hospital Universitario del Vinalopó, 03010 Alicante, Spain; nequima87@hotmail.com

Twitter Cesar DiazTorne @cesardiaztorne, Enrique Calvo Aranda @enriquecalvoa and Francisca Sivera @FranciscaSivera

Contributors NQ and MA designed the study. All authors provided substantial data. NQ wrote the draft and all authors approved the final version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests MA declares speaking fees and research grants from GlaxoSmithKline, Menarini and Horizon. The rest of the authors declare no conflicts of interest in the making of the present manuscript.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The study was approved by the ethics review board of the Hospital General Universitario de Alicante (2017/02 Act). Informed consent was not needed due to the retrospective nature of the analysis.

Provenance and peer review Not commissioned; internally peer reviewed.

Table 1 Main clinical and laboratory data of the whole sample (patients developing allopurinol-related cutaneous adverse reactions) and of those who showed after switching to febuxostat

<table>
<thead>
<tr>
<th>Age, in years</th>
<th>Skin reaction with allopurinol (n=67)</th>
<th>Skin reaction with febuxostat (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males, n (%)</td>
<td>49 (73.1%)</td>
<td>5 (50%)</td>
</tr>
<tr>
<td>Type of reaction, n (%)</td>
<td>55 (82.1%)</td>
<td>8 (80%)</td>
</tr>
<tr>
<td>Non-specific</td>
<td>9 (13.4%)</td>
<td>1 (10%)</td>
</tr>
<tr>
<td>Maculopapular</td>
<td>3 (4.5%)</td>
<td>1 (10%)</td>
</tr>
<tr>
<td>SJS</td>
<td>67.0 (44.9–89.3)</td>
<td>78.8 (42.8–90.6)</td>
</tr>
<tr>
<td>Glomerular filtration rate, in mL/min</td>
<td>8.4 (7.8–9.9)</td>
<td>8.1 (5.1–9.9)</td>
</tr>
<tr>
<td>Serum urate, in mg/dL</td>
<td>300 (138–300)</td>
<td>40 (40–80)</td>
</tr>
<tr>
<td>Dose at time of CAR, in mg/day</td>
<td>100 (range 50–300)</td>
<td>80 (40–80)</td>
</tr>
</tbody>
</table>

Data shown as median (IQR), unless otherwise specified.

CAR, cutaneous adverse reaction; SJS, Stevens-Johnson syndrome.
Correspondence

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Quilis N, Vela P, Blanco Cáceres BA, et al. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-218226

Received 4 June 2020
Accepted 6 June 2020

► http://dx.doi.org/10.1136/annrheumdis-2020-218263


ORCID IDs
Neus Quilis http://orcid.org/0000-0001-7509-7212
Cesar Diaz-Torne http://orcid.org/0000-0001-6275-7699

Francisca Sivera http://orcid.org/0000-0002-3414-1667

REFERENCES